CryoLife Inc. (NYSE:CRY) shares were up 2% on Friday . The company traded as high as $15.65 and last traded at $15.63, with a volume of 97,005 shares changing hands. The stock had previously closed at $15.33.

A number of research analysts have recently weighed in on CRY shares. Zacks Investment Research upgraded CryoLife from a “hold” rating to a “strong-buy” rating and set a $18.00 price target for the company in a research report on Friday, August 12th. Canaccord Genuity reiterated a “buy” rating on shares of CryoLife in a research report on Tuesday, July 26th. Lake Street Capital initiated coverage on CryoLife in a research report on Wednesday, June 15th. They set a “buy” rating and a $15.00 price objective for the company. Piper Jaffray Cos. reiterated an “overweight” rating and set a $16.00 price objective on shares of CryoLife in a research report on Wednesday, July 27th. Finally, Ladenburg Thalmann cut CryoLife from a “buy” rating to a “neutral” rating and set a $12.00 price objective for the company. in a research report on Thursday, April 28th. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $15.00.

The stock has a 50 day moving average price of $13.99 and a 200 day moving average price of $12.03. The firm has a market cap of $534.50 million and a PE ratio of 50.22.

CryoLife (NYSE:CRY) last announced its quarterly earnings results on Monday, July 25th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.11. The business had revenue of $47.10 million for the quarter, compared to analyst estimates of $35.50 million. The company’s revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.03 EPS. On average, equities research analysts predict that CryoLife Inc. will post $0.24 earnings per share for the current year.

In other CryoLife news, Director Ronald D. Mccall sold 10,000 shares of the business’s stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $11.56, for a total transaction of $115,600.00. Following the completion of the transaction, the director now owns 156,248 shares in the company, valued at approximately $1,806,226.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director C Elkins Ronald sold 2,000 shares of the business’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total value of $28,000.00. Following the transaction, the director now owns 103,586 shares of the company’s stock, valued at approximately $1,450,204. The disclosure for this sale can be found here.

An institutional investor recently raised its position in CryoLife stock. Morgan Stanley boosted its stake in shares of CryoLife Inc. (NYSE:CRY) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,605,563 shares of the company’s stock after buying an additional 21,067 shares during the period. Morgan Stanley owned approximately 5.64% of CryoLife worth $17,308,000 at the end of the most recent reporting period.

CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.